Bayer AG ((BAYRY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bayer AG is conducting a post-marketing surveillance study titled ‘Post Marketing Surveillance Study for Jivi (Damoctocog Alfa Pegol) in Korean Patients With Hemophilia A.’ The study aims to assess the safety of damoctocog alfa pegol, a treatment for hemophilia A, in Korean patients who have previously used other treatments. This research is significant as it seeks to provide real-world safety data for a drug already approved for preventing or treating bleeding episodes in hemophilia A patients.
Intervention/Treatment: The study focuses on damoctocog alfa pegol, a drug designed to replace the missing clotting factor 8 in patients with hemophilia A, thereby preventing or treating bleeding episodes. It is marketed under the name Jivi and is already approved for use in patients aged 12 and older.
Study Design: This is an observational cohort study with a prospective time perspective. Participants will continue their routine medical visits without any additional interventions, and data will be collected from their health records over a 36-week period.
Study Timeline: The study began in December 2023, with primary data collection expected to be completed by March 2026. The most recent update to the study was submitted in September 2025, indicating ongoing data collection and analysis.
Market Implications: The study’s findings could influence Bayer’s stock performance by providing insights into the safety of Jivi in a real-world setting, potentially affecting investor sentiment. As Bayer competes in the hemophilia treatment market, positive safety data could strengthen its position against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.